News & Updates
Filter by Specialty:
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
05 Mar 2022
byNatalia Reoutova
A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
05 Mar 2022
Physically active women less reliant on pain meds for headache
05 Mar 2022
byNatalia Reoutova
A cross-sectional study by the German Migraine and Headache Society reports a lower use of analgesics among physically active women prone to headaches vs physically inactive counterparts.
